Headlines

Oxford PV’s Henry Snaith named 2017 Citation Laureate

26 September 2017
Perovskite solar technology leader’s Co-Founder & Chief Scientific Officer honoured for his contribution to the discovery and application of perovskite materials to achieve efficient energy conversion.
Read

Oxford PV among Technology Review’s top 50 most innovative companies of 2017

13 September 2017
Oxford Photovoltaics (Oxford PV), the leader in the field of perovskite solar cells, has been named as one of the top 50 most innovative companies in the world, by the German edition of MIT Technology Review
Read

Changing the Face of Wastewater Treatment with Arvia’s Advanced Process

1 September 2017
The Challenge - Existing tertiary treatment technologies can be split into two process categories, concentration or destruction. Concentration processes such as adsorption and membrane processes concentrate problem compounds onto a solid.
Read

Successful Treatment of Diclofenac

1 September 2017
Arvia’s treatment process has proven capable of removing various problematic compounds, including those specified in EU and UK regulations – some of the strictest in the worldIn various trials of Diclofenac treatment, Arvia has demonstrated removal to well below the existing regulated limit from the outset of treatment.
Read

Exosect advances in microbial delivery with sprayable formulation of virus

3 August 2017
Exosect Ltd, a pioneer in Lean Formulation Technology™, has released positive interim results from its virus formulation development programme which is seeking to overcome the formulation challenges associated with virus delivery in agriculture.
Read

Lein closes first tranche of funding round

3 July 2017
Lein closed the first tranche of its current funding round at the start of the summer with investment from a syndicate of investors.
Read

Exosect signs first formulation out-licence deal

13 March 2017
Winchester, UK – Exosect Ltd., a pioneer in Lean Formulation Technology®, today announced that it has signed its first commercial agreement with a leading agrochemical company. The formulation, uses Exosect’s proprietary formulation platform Entostat®, to deliver a combination of two chemistries at significantly reduced rates, and has created a novel, proprietary insecticidal formulation for its partner.
Read

Large multicentre rheumatoid arthritis DCE-MRI study published

17 February 2017
A new publication in European Radiology demonstrates the sensitivity of DCE-MRI in distinguishing treatments in rheumatoid arthritis of the hand and wrist as early as 6 weeks after commencing treatment.Full citation (open access): J.C. Waterton, M. Ho, L.H. Nordenmark, M. Jenkins, J. DiCarlo, G. Guillard, C. Roberts, G. Buonaccorsi, G.J.M. Parker, M.A. Bowes, C. Peterfy, H. Kellner, P.C. Taylor. Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting. European Radiology. (In press) http://doi.org/10.1007/s00330-017-4736-9
Read